TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30914970

Group type: EXPERIMENTAL
Intervention: Novel nutraceutical compound containing red yeast rice, polymethoxyflavones, and antioxidants, dosage and duration not available
Number of subjects: 0
Study: 30915015

Group type: EXPERIMENTAL
Intervention: Sleep Bruxism
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30915029

Group type: EXPERIMENTAL
Intervention: Acipimox administration with exercise
Number of subjects: 0
Study: 30915112

Group type: EXPERIMENTAL
Intervention: Preoperative TG levels in benign group (median 167.5 ng/mL)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Postoperative TG levels measured at 7-14 days, 4 weeks, 6 weeks, and 3 months
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Preexisting hypothyroidism and hyperthyroidism in malignant group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: TG elimination half-life
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Preoperative TG levels
Number of subjects: 50
Study: 30915273

Group type: EXPERIMENTAL
Intervention: Cabozantinib plus Erlotinib
Number of subjects: 0
Study: 30915620

Group type: EXPERIMENTAL
Intervention: Peer-support intervention to link veterans to health-related services after incarceration
Number of subjects: 16000
Study: 30915626

Group type: EXPERIMENTAL
Intervention: Phosphate-free formulation of etanercept (50 mg)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Prior formulation of etanercept (50 mg)
Number of subjects: 111
Study: 30915685

Group type: EXPERIMENTAL
Intervention: Ceftaroline
Number of subjects: 166

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 166
Study: 30915922

Group type: EXPERIMENTAL
Intervention: Atezolizumab (TECENTRIQ®) plus chemotherapy (Abraxane; nab®-Paclitaxel)
Number of subjects: 0
Study: 30915992

Group type: EXPERIMENTAL
Intervention: High-dose i.v. naloxone infusion (total dose 3.25 mg kg)
Number of subjects: 8
Study: 30915996

Group type: EXPERIMENTAL
Intervention: VCPD
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: ANI
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: PD
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: PLR
Number of subjects: 345
Study: 30916032

Group type: EXPERIMENTAL
Intervention: Photoplethysmographic signal monitoring during anaesthesia induction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Photoplethysmographic signal parameters
Number of subjects: 0
Study: 30916608

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30916659

Group type: EXPERIMENTAL
Intervention: Concentric pedaling-type interval exercise (CON)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Eccentric pedaling-type interval exercise (ECC)
Number of subjects: 30
Study: 30916661

Group type: EXPERIMENTAL
Intervention: Tumaini smartphone game intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 60
Study: 30916665

Group type: EXPERIMENTAL
Intervention: Smartphone with built-in accelerometer, gyroscope, and phone orientation sensor; used for 3 consecutive days at home.
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Smartphone with built-in accelerometer, gyroscope, and phone orientation sensor; used during clinic appointment.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (subjects without PD); measured using the same smartphone device.
Number of subjects: 150
Study: 30916768

Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation (SCS)
Number of subjects: 17
Study: 30917688

Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation
Number of subjects: 142
Study: 30917689

Group type: EXPERIMENTAL
Intervention: Subcutaneous implantable cardioverter-defibrillator shock at 65 J
Number of subjects: 282

Group type: COMPARATOR
Intervention: Suboptimal device position
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Lower body mass index
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Lower shock impedance
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: White race
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Appropriate system position
Number of subjects: 282
Study: 30917793

Group type: EXPERIMENTAL
Intervention: Microgrants ($2000) and financial incentives ($500) for increasing group PA
Number of subjects: 87
Study: 30917871

Group type: EXPERIMENTAL
Intervention: High dose interleukin-2 (HD IL-2)
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: High dose interleukin-2 (HD IL-2) alone
Number of subjects: 810
Study: 30918029

Group type: EXPERIMENTAL
Intervention: Rituximab (1000 mg)
Number of subjects: 0
Study: 30918039

Group type: EXPERIMENTAL
Intervention: MRI-EFW at 36 + 0 to 36 + 6 weeks of gestation
Number of subjects: 2004

Group type: COMPARATOR
Intervention: 2D US-EFW
Number of subjects: 2004
Study: 30918100

Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate (DMF) treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DMF treatment
Number of subjects: 0
Study: 30918874

Group type: EXPERIMENTAL
Intervention: Basal-bolus regimen in DM1 patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Basal-bolus regimen in DM2 patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of insulin doses normalized for body weight
Number of subjects: 0

Group type: COMPARATOR
Intervention: Relationship of b/T ratio with glycemic control and hypoglycemia
Number of subjects: 0
Study: 30918950

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus cobimetinib
Number of subjects: 150
Study: 30919658

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: COMPARATOR
Intervention: Nonmedicated ADHD
Number of subjects: 19
Study: 30920187

Group type: EXPERIMENTAL
Intervention: Current opioid agonist treatment (buprenorphine maintenance)
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Current mutual-help group attendance
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Current outpatient counseling
Number of subjects: 375
Study: 30920244

Group type: EXPERIMENTAL
Intervention: Behavioral Activation System (BAS) measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral Inhibition System (BIS) measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pain intensity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Frontal alpha asymmetry (FAA)
Number of subjects: 0
Study: 30920851

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 17000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17000
Study: 30921081

Group type: EXPERIMENTAL
Intervention: Apical suspension
Number of subjects: 236

Group type: COMPARATOR
Intervention: No apical suspension
Number of subjects: 236
Study: 30921255

Group type: EXPERIMENTAL
Intervention: Children with PMS who are continent
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Children with PMS who are incontinent
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Children with PMS receiving gastrointestinal specialty care
Number of subjects: 17
Study: 30922100

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 664
Study: 30922152

Group type: EXPERIMENTAL
Intervention: Group progressive resistance training
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Treadmill training
Number of subjects: 54

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 54
Study: 30922241

Group type: EXPERIMENTAL
Intervention: Jehovah's Witnesses patients after cardiac surgery
Number of subjects: 31
Study: 30922248

Group type: EXPERIMENTAL
Intervention: Icaritin 600 or 800 mg b.i.d.
Number of subjects: 20
Study: 30922265

Group type: EXPERIMENTAL
Intervention: Balloon tamponade (Group A)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Balloon tamponade and bilateral uterine artery ligation (Group B)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Bilateral uterine artery ligation and cervix as natural tamponade (Group C)
Number of subjects: 125
Study: 30922276

Group type: EXPERIMENTAL
Intervention: Methylnaltrexone
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Enemas, methylnaltrexone, or 4-l polyethylene-glycol solution
Number of subjects: 327

Group type: COMPARATOR
Intervention: Oxycodone
Number of subjects: 327

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 327

Group type: COMPARATOR
Intervention: Morphine equivalent daily dose
Number of subjects: 327
Study: 30922283

Group type: EXPERIMENTAL
Intervention: Multi-level intervention on IPV reduction
Number of subjects: 620
Study: 30922315

Group type: EXPERIMENTAL
Intervention: T1DM patients with poor glycemic control
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: T1DM patients with optimal glucose control
Number of subjects: 26

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: T1DM patients (varied glycemic control)
Number of subjects: 26
Study: 30922356

Group type: EXPERIMENTAL
Intervention: Music listening sessions (1-hour sessions provided by volunteer musicians)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Non-exposed group (no music listening sessions)
Number of subjects: 152
Study: 30922468

Group type: EXPERIMENTAL
Intervention: Hybrid PET/MRI
Number of subjects: 100
Study: 30922643

Group type: EXPERIMENTAL
Intervention: Chronic endometritis (CE) diagnosed by CD138 IHC staining
Number of subjects: 167

Group type: COMPARATOR
Intervention: No chronic endometritis (NCE)
Number of subjects: 167
Study: 30922805

Group type: EXPERIMENTAL
Intervention: Combination of pertuzumab, subcutaneous trastuzumab, and taxane chemotherapy
Number of subjects: 50
Study: 30922862

Group type: EXPERIMENTAL
Intervention: Cryoballoon focal ablation system (CbFAS) performed using side-by-side applications of 10 seconds, repeated at 3-month intervals until complete response (CR) was established.
Number of subjects: 80
Study: 30922870

Group type: EXPERIMENTAL
Intervention: Orsiro sirolimus-eluting coronary stent with biodegradable polymer
Number of subjects: 1356
Study: 30922934

Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia (32.0-34.0 °C)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Normothermia (36.0-37.5 °C)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Both interventions (THAPCA-OH and THAPCA-IH)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: 3-month VABS-II and PCPC outcomes
Number of subjects: 204
Study: 30923464

Group type: EXPERIMENTAL
Intervention: Selenium (200 μg/day) and Coenzyme Q10 (200 mg/day)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study: 30923749

Group type: EXPERIMENTAL
Intervention: Multi-component quality improvement (QI) strategy
Number of subjects: 1146
Study: 30923820

Group type: EXPERIMENTAL
Intervention: anti-PD-1 therapy (pembrolizumab or nivolumab)
Number of subjects: 185
Study: 30924406

Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccines (PCVs) - ≥1 dose ≥ age 2 months
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Early onset otitis media (OM)
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Frequent OM episodes (≥8 episodes)
Number of subjects: 610

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 610
Study: 30924548

Group type: EXPERIMENTAL
Intervention: Caregivers of patients with GA impairments
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Caregivers of patients with higher numbers of GA domain impairments
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Caregivers of patients with impaired function
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Caregivers of patients with impaired nutrition
Number of subjects: 414
Study: 30924579

Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 1887

Group type: COMPARATOR
Intervention: Insulin glargine U100
Number of subjects: 1887
Study: 30924606

Group type: EXPERIMENTAL
Intervention: Robot-assisted sacrocolpopexy (RASC)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Supracervical hysterectomy with sacrocervicopexy (RSHS)
Number of subjects: 305
Study: 30924737

Group type: EXPERIMENTAL
Intervention: Lanreotide
Number of subjects: 44

Group type: COMPARATOR
Intervention: Octreotide LAR
Number of subjects: 44
Study: 30924789

Group type: EXPERIMENTAL
Intervention: ExPRESS mobile phone app for monitoring early signs, basic symptoms, and psychotic symptoms used for 6 months.
Number of subjects: 18
Study: 30924924

Group type: EXPERIMENTAL
Intervention: BRV (100 mg, intravenous)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: BRV (200 mg, intravenous)
Number of subjects: 13

Group type: COMPARATOR
Intervention: LEV (1500 mg, intravenous)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: BRV (50-100 mg, oral, twice-daily for 4 days)
Number of subjects: 13

Group type: COMPARATOR
Intervention: LEV (250-600 mg, oral, 4 hours postdose)
Number of subjects: 13
Study: 30924938

Group type: EXPERIMENTAL
Intervention: Infusion of 6'6'H2 glucose
Number of subjects: 57
Study: 30925139

Group type: EXPERIMENTAL
Intervention: High parent-reported stress
Number of subjects: 689

Group type: EXPERIMENTAL
Intervention: Moderate parent-reported stress
Number of subjects: 689

Group type: COMPARATOR
Intervention: Low parent-reported stress
Number of subjects: 689
Study: 30925890

Group type: EXPERIMENTAL
Intervention: Simulator-based practice sessions with practice coordinators
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Simulator-based practice sessions
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Ongoing support and scheduling of practice sessions
Number of subjects: 125
Study: 30926067

Group type: EXPERIMENTAL
Intervention: MRI measurements
Number of subjects: 150
Study: 30926081

Group type: EXPERIMENTAL
Intervention: Decitabine 30 mg plus cedazuridine 100 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Decitabine 40 mg plus cedazuridine 100 mg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Intravenous decitabine
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Overall adverse events
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Adverse events leading to death
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Progressive disease and respiratory failure
Number of subjects: 44
Study: 30926187

Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 1216

Group type: COMPARATOR
Intervention: Clinical evaluation
Number of subjects: 1216
Study: 30926572

Group type: EXPERIMENTAL
Intervention: Salivary microRNA panel (4 microRNAs)
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Salivary microRNAs
Number of subjects: 443
Study: 30927064

Group type: EXPERIMENTAL
Intervention: Higher-dairy diets (Q4, 274-1429 g/day dairy)
Number of subjects: 1655
Study: 30927096

Group type: EXPERIMENTAL
Intervention: Women (726 patients)
Number of subjects: 2087

Group type: COMPARATOR
Intervention: Men (1361 patients)
Number of subjects: 2087

Group type: EXPERIMENTAL
Intervention: Propensity score-matched cohort (506 patients)
Number of subjects: 2087
Study: 30927531

Group type: EXPERIMENTAL
Intervention: BMS plus DCB (PRO-Kinetic Energy BMS stent followed by Pantera Lux DCB)
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: BMS plus DCB
Number of subjects: 432
Study: 30928173

Group type: EXPERIMENTAL
Intervention: FSME-IMMUN vaccination after 3-dose primary immunization
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: First booster of FSME-IMMUN
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Second booster of FSME-IMMUN
Number of subjects: 358
Study: 30928393

Group type: EXPERIMENTAL
Intervention: Combination of age, BMI, PlGF, and MMP9 for OSA identification
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: BMI alone
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Age alone
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: PlGF alone
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: MMP9 alone
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Clinical measures and biomarkers combined
Number of subjects: 361
Study: 30928907

Group type: EXPERIMENTAL
Intervention: Baseline measurements of heart rate variability (HRV) and median nerve conduction velocity (NCV) prior to long-term occupational lead exposure
Number of subjects: 328
Study: 30928934

Group type: EXPERIMENTAL
Intervention: High fibre intake
Number of subjects: 57053

Group type: EXPERIMENTAL
Intervention: Red meat intake
Number of subjects: 57053

Group type: EXPERIMENTAL
Intervention: Processed meat intake
Number of subjects: 57053
Study: 30928955

Group type: EXPERIMENTAL
Intervention: Lateral positioning
Number of subjects: 74

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 74
Study: 30929153

Group type: EXPERIMENTAL
Intervention: PA-adjusted WOMAC pain scores (adjusted for step count)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: PA-adjusted WOMAC pain scores (adjusted for energy expenditure)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Unadjusted WOMAC pain score
Number of subjects: 122
Study: 30929188

Group type: EXPERIMENTAL
Intervention: Blephapad Combo treatment arm (wet wipes with terpinen-4-ol and hyaluronic acid)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard treatment arm (wet and warm gauze)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Blephapad Combo treatment arm
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard treatment arm
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 18
Study: 30929225

Group type: EXPERIMENTAL
Intervention: Medical exercise therapy for 3 months
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Medical exercise therapy
Number of subjects: 16
Study: 30929556

Group type: EXPERIMENTAL
Intervention: Balloon Dilation (BD)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 75

Group type: COMPARATOR
Intervention: Stent
Number of subjects: 75
Study: 30929571

Group type: EXPERIMENTAL
Intervention: Dynamic retinal vessel analysis (DVA) measuring maximum venular dilation (vMax) in response to flicker light stimulation.
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Dynamic retinal vessel analysis (DVA) measuring maximum arteriolar dilation (aMax) and venular dilation (vMax).
Number of subjects: 214
Study: 30929678

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate 22.5-mg depot
Number of subjects: 163
Study: 30929749

Group type: EXPERIMENTAL
Intervention: WHO 2015 guidelines for treatment eligibility
Number of subjects: 1190

Group type: COMPARATOR
Intervention: EASL 2017 guidelines for treatment eligibility
Number of subjects: 1190
Study: 30929841

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 392

Group type: COMPARATOR
Intervention: Carboplatin-based chemotherapy
Number of subjects: 392

Group type: COMPARATOR
Intervention: Carboplatin-gemcitabine
Number of subjects: 392
Study: 30930133

Group type: EXPERIMENTAL
Intervention: Regular Insulin (RI) on TPN
Number of subjects: 161

Group type: COMPARATOR
Intervention: Glargine Insulin (GI)
Number of subjects: 161
Study: 30931323

Group type: EXPERIMENTAL
Intervention: Laparoscopic Vecchietti's operation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (healthy women)
Number of subjects: 15
Study: 30931426

Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 15
Study: 30931695

Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 85

Group type: COMPARATOR
Intervention: Fuji IX GP Extra
Number of subjects: 85

Group type: COMPARATOR
Intervention: Fuji II LC
Number of subjects: 85
Study: 30931726

Group type: EXPERIMENTAL
Intervention: DCB angioplasty in CLI patients
Number of subjects: 156

Group type: COMPARATOR
Intervention: DCB angioplasty in IC patients
Number of subjects: 156
Study: 30931746

Group type: EXPERIMENTAL
Intervention: TAMP bioactive glass scaffolds
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (left empty)
Number of subjects: 6
Study: 30932132

Group type: EXPERIMENTAL
Intervention: Participants meeting the protein recommendation (0.8 g/kg/d)
Number of subjects: 11680

Group type: COMPARATOR
Intervention: Participants not meeting the protein recommendation (0.8 g/kg/d)
Number of subjects: 11680

Group type: COMPARATOR
Intervention: Participants aged over 70 years not meeting the protein recommendation
Number of subjects: 11680
Study: 30932170

Group type: EXPERIMENTAL
Intervention: Granisetron (3 mg)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control (no granisetron)
Number of subjects: 240
Study: 30932287

Group type: EXPERIMENTAL
Intervention: EPIMix
Number of subjects: 82

Group type: COMPARATOR
Intervention: Routine clinical MRI
Number of subjects: 82
Study: 30933618

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30935383

Group type: EXPERIMENTAL
Intervention: Local treatment with radical prostatectomy, limited duration systemic therapy for a total of six months (leuprolide, abiraterone acetate with prednisone, and apalutamide), metastasis-directed stereotactic body radiotherapy (SBRT), and post-operative fractionated radiotherapy if pT ≥ 3a, N1, or positive margins are present.
Number of subjects: 0
Study: 30935391

Group type: EXPERIMENTAL
Intervention: C4Ma3
Number of subjects: 984

Group type: EXPERIMENTAL
Intervention: C4Ma3 multiplied by fibrinogen
Number of subjects: 984

Group type: COMPARATOR
Intervention: Fibrinogen
Number of subjects: 984
Study: 30935397

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 33

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 33
Study: 30935734

Group type: EXPERIMENTAL
Intervention: Mesalazine
Number of subjects: 400

Group type: COMPARATOR
Intervention: Immunomodulators
Number of subjects: 400

Group type: COMPARATOR
Intervention: Anti-TNFα therapy
Number of subjects: 400

Group type: COMPARATOR
Intervention: Colectomy
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Baseline clinical severity, high baseline haemoglobin, week 4 clinical remission
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Antimicrobial peptide gene signature
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Abundance of Ruminococcaceae
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Abundance of Sutterella
Number of subjects: 400
Study: 30936057

Group type: EXPERIMENTAL
Intervention: Extracorporeal photopheresis (ECP) plus interleukin-2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30936738

Group type: EXPERIMENTAL
Intervention: Tanezumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tanezumab plus NSAID (naproxen, celecoxib, or diclofenac)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active comparator (naproxen, celecoxib, diclofenac, or oxycodone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active comparator
Number of subjects: 0